Microbot Medical Secures Strategic Midwest Expansion with LIBERTY® Robotic System Adoption in Michigan
Hingham, MA, June 9, 2026 – Microbot Medical Inc. (Nasdaq: MBOT), a leading innovator in endovascular robotics, has announced a significant milestone in the commercial rollout of its flagship LIBERTY® Endovascular Robotic System. One of the largest healthcare systems in Michigan has become the first in the state—and across the greater Midwest—to adopt the LIBERTY System, following the company’s recent entry into the North Carolina market.
Key Highlights for Investors
- Midwest Market Breakthrough: The adoption by a major Michigan health system marks LIBERTY’s first installation in the Midwest region, supporting the company’s full market release strategy and accelerating its expansion into new U.S. territories.
- Continued Commercial Progress: This comes on the heels of Microbot Medical’s initial U.S. healthcare system customer in North Carolina, reflecting growing recognition and demand for advanced robotic solutions in peripheral endovascular procedures.
- Large Addressable Market: The U.S. market for peripheral endovascular procedures is estimated at around 2.5 million cases annually, representing a substantial and growing commercial opportunity for the company.
- First and Only FDA-Cleared System: LIBERTY is currently the only FDA-cleared, single-use, remotely operated robotic system specifically designed for peripheral endovascular procedures.
- Regulatory Expansion: The LIBERTY System also recently received regulatory approval from the Israeli Ministry of Health’s AMAR Division, granting the company the ability to market and sell the system in Israel.
Details and Strategic Impact
Microbot Medical’s rapid progress in both new and established sales territories signals an inflection point for the adoption of robotic technology in vascular care. The company notes that major health systems are increasingly ready to integrate robotics into routine vascular procedures, driven by the twin imperatives of improving procedural outcomes and enhancing physician well-being by reducing radiation exposure and physical strain.
Chairman, President, and CEO Harel Gadot commented: “The addition of another healthcare system customer, following our recent expansion into North Carolina, reflects the growing recognition that robotics can be delivered in a way that is practical, accessible, and aligned with the needs of today’s healthcare environment. We are seeing increasing interest from physicians and hospital leaders who recognize LIBERTY’s potential to enhance procedural workflows while supporting physician well-being. We believe this positions us well for continued growth, increased utilization across our commercial accounts, and further market penetration.”
The LIBERTY System stands out in the market for its single-use, remote operation, and precision navigation, which aims to decrease radiation exposure and physician fatigue—a significant selling point for large hospital systems seeking to improve staff safety and operational efficiency.
Potentially Price-Sensitive Information
- Market Strategy Execution: The company is demonstrating successful execution of its U.S. market release strategy, with notable wins in strategically important regions. Each new health system adoption is a tangible indicator of commercial traction and could positively influence investor sentiment and the company’s valuation.
- Regulatory Momentum: Recent regulatory approval in Israel expands the company’s addressable market and could open additional revenue streams outside the U.S.
- Growing Interest and Validation: The reported growing interest from physicians and hospital leaders, combined with the LIBERTY System’s unique FDA-cleared status, underscores its competitive advantage and the potential for increased adoption, which may be significant for future revenue growth.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution for precision, efficiency, and safety in vascular care. Microbot is supported by a robust intellectual property portfolio and a commitment to innovation.
For further information, visit www.microbotmedical.com and connect on LinkedIn and X.
Forward-Looking Statements and Risks
This article contains forward-looking statements, including but not limited to, expectations regarding future adoption, growth, and commercialization of the LIBERTY System, as well as regulatory milestones and market expansion. These statements are subject to risks and uncertainties, including market conditions, regulatory outcomes, commercial adoption rates, intellectual property maintenance, and geopolitical risks. Investors should review the “Risk Factors” section in Microbot Medical’s SEC filings for a detailed discussion of these risks.
Disclaimer: This report is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisor prior to making investment decisions. The views expressed herein are based on the company’s public disclosures as of the date of publication and may be subject to change without notice.
